Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of
the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal …

Abstract Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with
grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well …

Abstract C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal
immunoglobulin deposition caused by alternative complement pathway dysregulation …

Background Hyperactivity of the alternative complement pathway is the principle defect in
C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds C5 to prevent …

C3 glomerulopathy (C3G) is a prototypic complement-mediated kidney disease. Rapidly
progressive forms of C3G usually respond poorly to conventional treatments. We report on …

C3 glomerulonephritis (C3GN) is a disorder of excess alternative complement activation
leading to glomerular injury. Following kidney transplantation, C3GN has a high recurrence …

Eculizumab might benefit C3 glomerulopathies mediated by dysregulation of the alternative
complement pathway. Here, we report renal biopsy findings before and after eculizumab …

Abstract Background C3 glomerulonephritis (C3GN) can be a devastating disease with poor
response to immunosuppressive therapy. Complement inhibition with eculizumab has had …

Abstract Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by
dysregulation of the complement pathway. Based on its pathophysiology, treatment with the …

Background Cases reports and small series of patients with C3 glomerulopathy have
reported variable efficacy of eculizumab. Study Design Case series of C3 glomerulopathy …